DOCSLIB.ORG

Cardiorenal Syndromes Presentation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cardiorenal Syndromes Presentation Outline Cardiorenal Syndromes: New ° Definitions Insights into Combined Heart and Kidney Failure ° Complex, bidirectional pathogenesis ° Novel diagnostic targets Peter A. McCullough, MD, MPH ° Therapy FACC, FACP, FAHA, FCCP, FNKF ° Putting it all together History Outline •1913: Sir Thomas Lewis gave a clinical lecture on paroxysmal dyspnoea in cardiocardio--renalrenal patients with special reference to “cardiac” and “uremic” asthma •1951: the term cardiorenal syndromes (CRS) was coined by Ledoux [i] •1997 to present: Schrier in multiple papers summarized the impact of salt and ° Definitions water retention combined with neurohormonal activation in the pathogenesis of CRS. [ii] [iii] [iv] ° Complex, bidirectional pathogenesis •2003: Brammah and colleagues pointed out that treatment of bilateral renal arterial disease could result in improvement of both heart and kidney function. [v] •2005: Braam demonstrated in animals that organ dysfunction in one system ° Novel diagnostic targets influences that in the other. [vi] •2008: Ronco and colleagues proposed five distinct CRS according to the temporal sequence of organ injury and failure as well as the clinical context. [vii] ° Therapy •2008: Acute Dialysis Quality Initiative (ADQI) involving nephrology, critical care, cardiac surgery, and cardiology was convened. [viii] ° Putting it all together •2011: Karger launches “Cardiorenal Medicine” James Sowers, MD, Editor •2012: ADQI conducted a second consensus conference to review the spectrum of pathophysiologic mechanisms involved in CRS [i] University College Hospital, London, November 12th, 1913. BMJ 2: 1417–1420. Ledoux P. [Cardiorenal syndrome]. Avenir Med. 1951 Oct;48(8):149-53. [ii] Blair JE, Manuchehry A, Chana A, Rossi J, Schrier RW, Burnett JC, Gheorghiade M. Prognostic markers in heart failure-congestion, neurohormones, and the cardiorenal syndrome. Acute Card Care. 2007;9(4):207-13. [iii] Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol. 2009 Dec;4(12):2013-26. [iv] Sarraf M, Schrier RW. Cardiorenal syndrome in acute heart failure syndromes. Int J Nephrol. 2011 [v] Brammah A, Robertson S, Tait G, Isles C. Bilateral renovascular disease causing cardiorenal failure. BMJ. 2003 Mar 1;326(7387):489-91. [vi] Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J. 2005 Jan;26(1):11-7. [vii] Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008 Nov 4;52(19):1527-39. [viii] Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House A, Katz NM, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P; Acute Dialysis Quality Initiative (ADQI) consensus group. Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2010;165:54-67. 1 Five Cardiorenal Syndromes Recognition of Cardiorenal Cardiorenal Syndrome (CRS) General Definition: Syndrome A pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ CRS Type I (Acute Cardiorenal Syndrome) Abrupt worsening of cardiac function (acutely decompensated congestive heart failure) leading to acute kidney injury CRS Type II ( Chronic Cardiorenal Syndrome) Chronic abnormalities in cardiac function (chronic congestive heart failure) causing progressive and permanent chronic kidney disease CRS Type III (Acute Renocardiac Syndrome) Abrupt worsening of renal function (acute kidney ischaemia or tubular injury) causing acute cardiac disorder (new or decompensated heart failure) CRS Type IV (Chronic Renocardiac Syndrome) Chronic kidney disease (diabetic nephropathy) contributing to decreased cardiac function, cardiac hypertrophy and/or increased risk of adverse cardiovascular events CRS Type V (Secondary Cardiorenal Syndrome) Systemic condition (e.g. sepsis) causing both cardiac and renal dysfunction Ronco C, McCullough PA, Anker SD, et al; Acute Dialysis Quality Initiative (ADQI) consensus group. Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2010;165:54 -67. Definition of Acute Kidney Injury (KDIGO Guidelines 2012) 2 Risk of Worsening Renal Function (WRF) by Number of Risk Factors Characteristics Adjusted OR 6.0 Women 1.41 HTN 1.64 53% 5.0 Rales>Bases 1.28 HR >100 bpm 1.34 38% 4.0 SCr ≥1.5 mg/dL 1.77 SBP >200 mm Hg 1.63 29% 3.0 (%) 24% 2.0 Risk of WRF Risk 16% 1.0 0.0 ≤ 1 2 3 4≥ 5 No. of Risk Factors N=1,681, WRF, defined as a rise in serum creatinine of >0.3 mg/dl (26.5 µmol/l). Krumholz HM et al. Am J Cardiol . 2000;85:1110. Outline ° Definitions ° Complex, bidirectional pathogenesis ° Novel diagnostic targets ° Therapy ° Putting it all together 3 High Central Venous Pressure and Cardiorenal Syndrome JACC Vol. 53, No. 7, 2009 Cardio-Renal Syndrome Pathophysiology Venous Congestion and Glomerular CKD-Associated Myocardial Chan.es Systolic or Diastolic Dysfunction or oth Myocyte hypertrophy Myocyte dysfunction Altered Intra-renal Hemodynamics Filtration &&Inters,,al Fibrosis 2Capillary density &&L/ Mass Ele3ated serum troponin le3els Increased CKD-Associated /ascular Chan.es Decreased Perfusion 3enous Accelerated atherosclerosis pressure Renal &/ascular s,@ness Con.estion 2Smooth muscle density Precipitators Osteoblastic /SMC transformation Diuretics /asodilators Intra-and extracellular calcification Procedures Toxicity /ascocostriction Acute on Acute on Chonic Chronic Cardiac Acute Neurohoromonal Acti3ation Kidney Disease SNS+RAS+Aldosterone+ Endothelin+ADH+1 renal In0ury Chronic Neurohormonal 3asoconstriction 8adenosine9+prosta.landin DM+HTN + other CKD &SNS1 RAS1 Aldosterone dysre.ulation Renal hypoperfusion 2/itamin D Decreased GFR &PTH Resistence to diuretics &PO5 LV Failure Resistance to ANP/BNP Mechanisms Hypotestesteronism Na + H 2O retention • Pressure overload ANP/ locked 2EPO • Volume overload NP Natruretic Peptides Natriuresis Necrosis / apoptosis 2Fe u,li7a,on • Cardiomyopathy Fibrosis 2Na-K ATPase Humoral Anemia/Rela,3e 2Epo/Fe transport blocked Cytokine Biomarkers si.nallin. Incitin. E3ents secretion ↑BNP/NT-proBNP 2Medical compliance ↑ N-GAL IL-11 TNF- 2Tubulo- &Sodium intake ↑ KIM-1 Alpha Glomerular Ischemia Leukocyte Function ↑IL-18 Endothelial Arrhythmias 8AF9 Acti3ation Catalytic iron Dysfunction OSAS ↑Cysta,n-C &Cytokines1 &Adhesion Molecules1 &En7yma,c Ac,3a,on1 &Oxida,3e Stress &Crea,nine Added Insults -rine albumin NSAIDS1 T:Ds Many others McCullou.h PA1 Die7 J1 KDIGO 2010 Workshopt1 Adapted1 Courtesy Ronco1 C 2009 4 Tubular Recovery and Renal Reserve in AKI ~30% of In-hospital AKI results in permanent loss in eGFR (~5% ESRD) Outline ~70% must have had tubular recovery or compensation by the remaining nephrons ° Definitions ° Complex, bidirectional pathogenesis ° Novel diagnostic targets ° Therapy ° Putting it all together Adapted fromThadhani et al., N Engl J Med 1996 BOLD MRI History of Urine in Western Medicine Power Doppler ° Ancient Babylonian and Sumerian physicians Clinical Evaluation first inscribed their And Biomarkers evaluations of urine into clay tablets as early as Positron Emission Tomography 4,000 B.C. Figure: People showing for a diagnose a sample of their urine to the physician Constantine the African. Advanced Imaging Yoquinto, My Health Daily News, Aug 15 2011 5 Blood and Urine Biomarkers of Acute Kidney Injury G1 cell cycle arrest markers ([TIMP-2].[IGFBP7]) NGAL, IL-18, KIM-1, L-FABP Tubular Enzymuria GGT, AlkPhos, LDH Cr, Cystatin-C NAG, α/πGST, Adapted from Geraghty et al. Am J Physiol Renal Physiol. 1992; 263: 958-962, Westhuyzen, et al, NDT 2003, Endre Z, 2008, Kashani Crit Care 2013 Predicted AKI Detection Multimarker Panel Approach Diagnostic value of biomarker Single Combination Liangos et al., Biomarkers 2008 0.50-0.66 0.78 Han et al., Clin JASN 2009 0.59-0.68 0.80-0.84 Kashani K et al, Crit Care 2013 0.76-0.79 0.80 Inducers of G1 cell cycle arrest (Urine [TIMP-2].[IGFBP7]) AKI Cystatin C Creatinine KIMKIM--11 IL 18IL 18 NGALNGAL 0 h 4 h 8 h 12 h 24 h 48 h Adapted Courtesy Herget-Rosenthal 2010 24 6 Baseline Samples and Prediction of AKI NEPHRO CHECK ® Test System: (TIMP-2 x IGFBP-7 Product in Spot Urine): Sapphire Study the Astute Medical NEPHRO CHECK ® Test System has received 510(k) clearance through FDA’s de novo classification process. On 9/5/14 FDA: “Current laboratory tests can only assess whether a patient may already have AKI; often, the patient has progressed to moderate to severe AKI before the test results confirm the clinical diagnosis. NephroCheck detects the presence of insulin-like growth-factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases (TIMP-2) in the urine, which are associated with acute kidney injury. Within 20 minutes, the test provides a score based on the amount of the proteins present that correlates to the patient’s risk of developing AKI within 12 hours of the test being performed. No other tests currently on the market are FDA- approved or cleared to assess the risk of developing AKI in at-risk patients.” 25 -rinary ATIMP-2BCAIGF P7B Discriminates Patients With AKI From Those Without AKI 8Topa7 Study9 ihorac et al1 AJRCCM 2015 7 NEPHRO CHECK ® AKIRisk™ NGAL is an endogenous bacteriostatic protein by Case #1 Positive Test Performed Score = 2.6 reducing available catalytic iron Day 1 Day 2 Day 3 Day 4 Day 5 Therapies Cardiac Surgery: 6 hrs. NGAL E. coli Pump timeE 1.5 hrs. Siderophore No Transfusion Serum Creatinine (SCr, mg/dL) 3x SCr Baseline 1.3 SCr Baseline Iron X Urine Output AKI (UO, mL/h) <0.5ml/kg/h for ≥12h 0.5 ml/kg/h bacterial without NGAL growth Fluid Balance +6.4L +9.5L +11.2L +12.5L (Cumulative) curves with NGAL Hours 0 12 24 36 48 60 72 84 96 108 Goetz et al.
Load more

Recommended publications
  • Central Nervous System Dysfunction As the First Manifestation of Multiple
    Bone Marrow Transplantation (2000) 25, 79–83 2000 Macmillan Publishers Ltd All rights reserved 0268–3369/00 $15.00 www.nature.com/bmt Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients B Gordon1, E Lyden2, J Lynch2, S Tarantolo3, ZS Pavletic3, M Bishop3, E Reed3, A Kessinger3 and W Haire3 Departments of 1Pediatrics, 2Preventive and Societal Medicine, and 3Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA Summary: Organ system dysfunction is a frequent complication of hematopoietic stem cell transplantation. Single and multior- Development of CNS dysfunction in the setting of hema- gan dysfunction may be due to the culmination of an uncon- topoietic stem cell transplant (HSCT) has been pre- trolled inflammatory response to some initial event, viously shown to predict for subsequent second organ mediated by an as yet incompletely understood interplay of dysfunction and death. In this paper, we describe the cytokines, complement, and the coagulation system. In the characteristics of this isolated CNS dysfunction, and its setting of acutely ill non-transplant patients, this has been relationship to multiple organ dysfunction syndrome termed the systemic inflammatory response syndrome.1 (MODS) after HSCT. Twenty-one of 186 patients This syndrome has been well described in patients with undergoing HSCT developed CNS dysfunction as their trauma or severe infection,1–3 but has only recently been first organ dysfunction a mean of 22.8 ± 0.9 days after recognized in patients undergoing HSCT. the start of the preparative regimen. Compared with The occurrence of single organ system dysfunction in 137 patients who developed no organ dysfunction, the post-transplant period has been shown to predict for patients presenting with CNS dysfunction were more subsequent development of multiple organ dysfunction and likely to have undergone allogeneic HSCT (P = 0.001) death.
    [Show full text]
  • Cardiorenal Syndrome in Patients with Heart Failure
    CARDIORENAL SYNDROME IN PATIENTS WITH HEART FAILURE IN KANO. A DISSERTATION SUBMITTED TO THE NATIONAL POSTGRADUATE MEDICAL COLLEGE OF NIGERIA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF FELLOWSHIP OF THE COLLEGE IN INTERNAL MEDICINE (CARDIOLOGY). BY DR MUHAMMAD NAZIR SHEHU M.B, B.S [B.U.K.] 2002 DEPARTMENT OF MEDICINE AMINU KANO TEACHING HOSPITAL, KANO. MAY 2014 i DECLARATION I hereby declare that this work is original unless otherwise acknowledged. This work has not been presented to any other College for Fellowship and has not been submitted elsewhere for publication. Signature---------------------------- Date---------------------- DR MUHAMMAD NAZIR SHEHU May 2014 ii CERTIFICATION I SUPERVISORS’ CERTIFICATION This study reported in this Dissertation was done by the candidate under our supervision. We also supervised the writing of the Dissertation. SUPERVISOR 1. SIGNATURE/DATE:……………………………………………….. Professor SA Isezuo (FMCP) Professor of Medicine and Consultant Physician/Cardiologist, Usman Danfodiyo University Teaching Hospital,Sokoto. 2. SIGNATURE/DATE:……………………………………………….. Professor B. N. Okeahialam, (FWACP). Professor of Medicine and Consultant Physician/Cardiologist, Jos University Teaching Hospital, Jos, Plateau State, Nigeria. 3. SIGNATURE/DATE:------------------------------------------------------- DR M. M. BORODO (FMCP) Associate Professor of Medicine and Consultant Physician/Gastroenterologist, Aminu Kano Teaching Hospital, Kano, Kano State, Nigeria. iii CERTIFICATION II HEAD OF DEPARTMENT’S CERTIFICATION This
    [Show full text]
  • Future Diagnostic & Therapeutic Targets in Cardiorenal Syndromes
    Future Diagnostic & Therapeutic Targets in Cardiorenal Syndromes (Biomarkers, advanced monitoring, advanced imaging, novel therapies) EDGAR V. LERMA, MD Clinical Professor of Medicine Secon of Nephrology UIC/ Advocate Christ Medical Center Oak Lawn, IL May 27, 2017 Disclosure of Interests • Honoraria: UpToDate, McGraw-Hill Publishing, Elsevier Publishing, Springer Publishing, Wolters-Kluwer Publishing, ACP Smart Medicine, Emedicine • Editorial Boards: American Journal of Kidney Diseases, ASN Kidney News, Clinical Journal of the American Society of Nephrology, Clinical Reviews in Bone and Mineral Metabolism, International Urology and Nephrology, Journal of Clinical Lipidology, Prescribers Letter, Renal and Urology News, Reviews in Endocrinology and Metabolic Disorders, Seminars in Dialysis • Speaker/ Advisory Board: Astute Medical, Mallinckrodt, Otsuka Pharmaceuticals, ZS Pharma KDIGO Controversies Conference on Heart Failure in CKD May 25-28, 2017 | Athens, Greece Disclosure of ABIM Service: Edgar V. Lerma, M.D. ▪ I am a current member of the ABIM Self-Assessment Committee. ▪ To protect the integrity of certification, ABIM enforces strict confidentiality and ownership of exam content. ▪ My participation in this CME activity is allowed under ABIM policy and is subject to the following: • As a member of an ABIM test committee, I agreed to keep exam information confidential, as it is owned exclusively by ABIM. • As is true for any ABIM candidate who has taken an exam for certification, I have signed the Pledge of Honesty in which I have agreed
    [Show full text]
  • Multiple Organ Dysfunction Syndrome Timothy G. Buchman, Ph.D., MD
    Physiologic Failure: Multiple Organ Dysfunction Syndrome Timothy G. Buchman, Ph.D., M.D. Edison Professor of Surgery Professor of Anesthesiology and of Medicine Washington University School of Medicine St. Louis, Missouri 63110 [email protected] Acknowledgement: This work was supported, in part, by award GM48095 from the National Institutes of Health 2 Buchman Humans, like other life forms, can be viewed as thermodynamically open systems that continuously consume energy to maintain stability in the internal milieu in the face of ongoing environmental stress. In contrast to simple unicellular life forms such as bacteria, higher life forms must maintain stability not only in individual cells but also for the organism as a whole. To this end, a collection of physiologic systems evolved to process foodstuffs; to acquire oxygen and dispose of gaseous waste; to eliminate excess fluid and soluble toxins; and to perform other tasks. These systems—labeled respiratory, circulatory, digestive, neurological, and so on—share several features. • Physiological systems are spatially distributed. Food has to get from mouth to anus. Urine is made in the kidneys but has to exit the urethra. Blood may be pumped by the heart but has to reach the great toe. • Physiologic systems are generally spacefilling and structurally fractal. Each cell has demand for nutrients; each cell excretes waste. Information has to travel from the brain throughout the body. While not every physiologic system is self-similar at all levels of granularity, there is typically a nested architecture that facilitates function: microvillus to villus to intestinal mucosa; alveolus to alveolar unit to bronchial segment; capillary to arteriole to artery.
    [Show full text]
  • Sepsis-3 Definitions. What Are They, and How Should We Use Them?
    Sepsis-3 definitions. What are they, and how should we use them? William T. Browne, MD, FCCM October 28, 2016 ACCP/SCCM Consensus Definitions • SIRS (Systemic Inflammatory Response Syndrome) – Temperature > 38° C or < 36° C – Heart rate > 90 – Respiratory rate > 20 or pCO2 < 32 mm Hg – WBC > 12,000 or < 4,000 or > 10% bands • Any two of the criteria needed for SIRS diagnosis ACCP/SCCM Consensus Definitions • Sepsis – Must have diagnosis of SIRS – Clinical evidence of infection • bacteremia • infiltrate on CXR • abscess on imaging study ACCP/SCCM Consensus Definitions • Severe sepsis – must have diagnosis of sepsis – evidence of organ dysfunction • Organ dysfunction – increase in BUN/creatinine – elevated LFTs – hypoxia – elevated serum lactate ACCP/SCCM Consensus Definitions • Septic shock – must have findings of severe sepsis – hypotension after adequate fluid resuscitation – systolic BP 40 mm Hg below baseline – may not have hypotension if receiving pressor agents Was this a useful bedside tool? Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection Under these new definitions Sepsis(new) = Severe Sepsis(old) Key concepts of sepsis (1) • Sepsis is the primary cause of death from infection, especially if not recognized and treated promptly. Its recognition mandates urgent attention • Sepsis is a syndrome shaped by pathogen factors and host factors (eg, sex, race and other genetic determinants, age, comorbidities, environment) with characteristics that evolve over time. What differentiates sepsis from infection is an aberrant or dysregulated host response and the presence of organ dysfunction. Key concepts of sepsis (2) • Sepsis-induced organ dysfunction may be occult; therefore, its presence should be considered in any patient presenting with infection.
    [Show full text]
  • Cardio-Renal Syndrome
    Kelly Li RSC Symposium 2017 . 40-50% of patients with HF have co-existing CKD (GFR<60) . Reductions in GFR strongly affect all-cause mortality in HF patients . CKD is a powerful independent risk factor for the development and progression of CVD and outcomes . >60% CKD patients have CVD, and degree of CVD correlates with CKD severity . Patients with stage 3 or higher CKD have a threefold higher risk of HF . Systemic disorders can cause both cardiac and renal dysfunction Schefold et al Nature Reviews Nephrology 2016 Comorbid conditions at end of year Australia 40 30 20 % % of patients Coronary 10 Peripheral vascular Lung Cerebrovascular 0 2005 2007 2009 2011 2013 2015 Suspected cases included 2016 ANZDATA Annual Report, Figure 2.10 Cause of death Deaths occurring during 2015 Australia New Zealand 100 80 60 Percent 40 20 0 HD PD Tx HD PD Tx Cardiovascular Withdrawal Cancer Infection Other 2016 ANZDATA Annual Report, Figure 3.5 Wali et al JACC 2005 Figure 2. Kaplan-Meier plot of cumulative incidence of cardiovascular death or unplanned admission to hospital for the management of worsening CHF stratified by approximate quintiles of eGFR in mL/min per 1.73 m2 (time in years). Hillege et al Circulation 2016 Schefold et al Nature Reviews Nephrology 2016 Schefold et al Nature Reviews Nephrology 2016 . Cardiorenal syndrome complex and bi-directional . Haemodynamic interactions . Neurohormonal dysregulation . Inflammation and other metabolic changes Schefold et al Nature Reviews Nephrology 2016 Schefold et al Nature Reviews Nephrology 2016 Schefold et al Nature Reviews Nephrology 2016 Schefold et al Nature Reviews Nephrology 2016 Schefold et al Nature Reviews Nephrology 2016 Schefold et al Nature Reviews Nephrology 2016 Schefold et al Nature Reviews Nephrology 2016 Schefold et al Nature Reviews Nephrology 2016 Schefold et al Nature Reviews Nephrology 2016 .
    [Show full text]
  • Cardiorenal Syndrome: Emerging Role of Medical Imaging for Clinical Diagnosis and Management
    Journal of Personalized Medicine Review Cardiorenal Syndrome: Emerging Role of Medical Imaging for Clinical Diagnosis and Management Ling Lin 1 , Xuhui Zhou 2,* , Ilona A. Dekkers 1 and Hildo J. Lamb 1 1 Cardiovascular Imaging Group (CVIG), Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; [email protected] (L.L.); [email protected] (I.A.D.); [email protected] (H.J.L.) 2 Department of Radiology, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen 510833, China * Correspondence: [email protected]; Tel.: +86-755-83982222 Abstract: Cardiorenal syndrome (CRS) concerns the interconnection between heart and kidneys in which the dysfunction of one organ leads to abnormalities of the other. The main clinical challenges associated with cardiorenal syndrome are the lack of tools for early diagnosis, prognosis, and evaluation of therapeutic effects. Ultrasound, computed tomography, nuclear medicine, and magnetic resonance imaging are increasingly used for clinical management of cardiovascular and renal diseases. In the last decade, rapid development of imaging techniques provides a number of promising biomarkers for functional evaluation and tissue characterization. This review summarizes the applicability as well as the future technological potential of each imaging modality in the assessment of CRS. Furthermore, opportunities for a comprehensive imaging approach for the evaluation of CRS are defined. Citation: Lin, L.; Zhou, X.; Dekkers, Keywords: cardiorenal syndrome; imaging biomarker; tissue characterization I.A.; Lamb, H.J. Cardiorenal Syndrome: Emerging Role of Medical Imaging for Clinical Diagnosis and Management. J. Pers. Med. 2021, 11, 1. Introduction 734. https://doi.org/10.3390/ Cardiorenal syndrome (CRS) is an umbrella term describing the interactions between jpm11080734 concomitant cardiac and renal dysfunctions, in which acute or chronic dysfunction of one organ may induce or precipitate dysfunction of the other [1].
    [Show full text]
  • Cardiorenal Syndrome
    Journal of the American College of Cardiology Vol. 52, No. 19, 2008 © 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.07.051 STATE-OF-THE-ART PAPER Cardiorenal Syndrome Claudio Ronco, MD,* Mikko Haapio, MD,† Andrew A. House, MSC, MD,‡ Nagesh Anavekar, MD,§ Rinaldo Bellomo, MD¶ Vicenza, Italy; Helsinki, Finland; London, Ontario, Canada; and Melbourne, Australia The term cardiorenal syndrome (CRS) increasingly has been used without a consistent or well-accepted defini- tion. To include the vast array of interrelated derangements, and to stress the bidirectional nature of heart- kidney interactions, we present a new classification of the CRS with 5 subtypes that reflect the pathophysiology, the time-frame, and the nature of concomitant cardiac and renal dysfunction. CRS can be generally defined as a pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction of 1 organ may induce acute or chronic dysfunction of the other. Type 1 CRS reflects an abrupt worsening of cardiac function (e.g., acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type 2 CRS comprises chronic abnormalities in cardiac function (e.g., chronic congestive heart failure) causing progressive chronic kidney disease. Type 3 CRS consists of an abrupt worsening of renal function (e.g., acute kidney isch- emia or glomerulonephritis) causing acute cardiac dysfunction (e.g., heart failure, arrhythmia, ischemia). Type 4 CRS describes a state of chronic kidney disease (e.g., chronic glomerular disease) contributing to decreased car- diac function, cardiac hypertrophy, and/or increased risk of adverse cardiovascular events.
    [Show full text]
  • Heart Failure
    Heart Failure Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist, Chief Academic and Scientific Officer St. John Providence Health System Providence Park Heart Institute Novi, MI USA e-mail: [email protected] Outline Definitions Complex, bidirectional pathogenesis Example of novel target Therapy Putting it all together Outline Definitions Complex, bidirectional pathogenesis Example of novel target Therapy Putting it all together Definition of Heart Failure (HF) •• TheThe failure of the heart as a pump resulting in inadequate cardiac output to peripheral tissues and stasis of blood in the lungs resulting most commonly in fatigue and pulmonary congestion.congestion. •• A complex mechanical and neurohumoral syndrome characterized by effort intolerance, fluid retention, and reduced longevity. •• At least 7 definitions in the literature based on tested scoring schemes and expert opinion. Heart Failure as a Clinical Clinical presentationSyndrome of acute kidney injury Stasis of blood, tissue deposition of water and salt resulting in effort intolerance, progressive dyspnea, fatigue, edema Definition and Classification of the Cardio-Renal Syndromes Cardio-Renal Syndromes (CRS) General Definition: Disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other Acute Cardio-Renal Syndrome (Type 1) Acute worsening of cardiac function leading to renal dysfunction Chronic Cardio-Renal Syndrome (Type 2) Chronic abnormalities in cardiac
    [Show full text]
  • Amiodarone-Induced Hypothyroidism Presenting As Cardiorenal Syndrome
    Hindawi Publishing Corporation Case Reports in Cardiology Volume 2012, Article ID 161450, 3 pages doi:10.1155/2012/161450 Case Report Amiodarone-Induced Hypothyroidism Presenting as Cardiorenal Syndrome Evan L. Hardegree1 and Robert C. Albright2 1 Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA 2 Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA CorrespondenceshouldbeaddressedtoEvanL.Hardegree,[email protected] Received 6 March 2012; Accepted 14 May 2012 Academic Editors: H. Kitaoka and A. J. Mansur Copyright © 2012 E. L. Hardegree and R. C. Albright. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Here we present the case of a 90-year-old man with chronic heart and renal failure who was admitted with what appeared to be a simple heart failure exacerbation. However, further investigation led to the diagnosis of profound amiodarone-induced hypothy- roidism as the cause of his acute decompensation, highlighting the importance of a broad differential diagnosis and thorough investigation. 1. Introduction (LVEF) of 15% with a dual-chamber pacemaker for car- diac resynchronization; paroxysmal atrial fibrillation and In patients with concurrent heart and renal failure (cardiore- frequent ven-tricular ectopy requiring initiation of amio- nal syndrome), common causes of decompensation may in- darone 6 months prior (200 mcg/day); stage IV chronic clude myocardial ischemia, excessive salt ingestion, and med- kidney disease, not on dialysis. The patient reported full ication noncompliance. However, there are many conditions compliance with his medical heart failure regimen and that may tip this delicate balance.
    [Show full text]
  • Cardiorenal Syndrome in Thalassemia Patients
    Makmettakul et al. BMC Nephrology (2020) 21:325 https://doi.org/10.1186/s12882-020-01990-8 RESEARCH ARTICLE Open Access Cardiorenal syndrome in thalassemia patients Sorasak Makmettakul1,2, Adisak Tantiworawit1* , Arintaya Phrommintikul3, Pokpong Piriyakhuntorn1, Thanawat Rattanathammethee1, Sasinee Hantrakool1, Chatree Chai-Adisaksopha1, Ekarat Rattarittamrong1, Lalita Norasetthada1, Kanda Fanhchaksai4 , Pimlak Charoenkwan4 and Suree Lekawanvijit5 Abstract Background: Cardiorenal syndrome (CRS), a serious condition with high morbidity and mortality, is characterized by the coexistence of cardiac abnormality and renal dysfunction. There is limited information about CRS in association thalassemia. This study aimed to investigate the prevalence of CRS in thalassemia patients and also associated risk factors. Methods: Thalassemia patients who attended the out-patient clinic of a tertiary care university hospital from October 2016 to September 2017 were enrolled onto this cross-sectional study. Clinical and laboratory findings from 2 consecutive visits, 3 months apart, were assessed. The criteria for diagnosis of CRS was based on a system proposed by Ronco and McCullough. Cardiac abnormalities are assessed by clinical presentation, establishment of acute or chronic heart failure using definitions from 2016 ESC guidelines or from structural abnormalities shown in an echocardiogram. Renal dysfunction was defined as chronic kidney disease according to the 2012 KDIGO guidelines. Results: Out of 90 thalassemia patients, 25 (27.8%) had CRS. The multivariable analysis showed a significant association between CRS and extramedullary hematopoiesis (EMH) (odds ratio (OR) 20.55, p = 0.016); thalassemia type [β0/βE vs β0/β0 thalassemia (OR 0.005, p = 0.002)]; pulmonary hypertension (OR 178.1, p = 0.001); elevated serum NT-proBNP (OR 1.028, p = 0.022), and elevated 24-h urine magnesium (OR 1.913, p = 0.016).
    [Show full text]
  • COVID-19 Recommendations for Health Care Workers (PDF)
    MINNESOTA DEPARTMENT OF HEALTH COVID-19 Recommendations for Health Care Workers 8 / 6 /2021 This guidance was updated on August 6, 2021, to include: . All health care workers, regardless of vaccination status, should be tested for SARS-CoV-2 when symptomatic, after a higher-risk exposure, and when working in a facility experiencing an outbreak. Post-exposure testing should occur immediately and at day 3–5 after exposure. Testing of HCW for COVID-19 Health care workers (HCW) should not work while sick, even if presenting with mild signs or symptoms. HCW with fever and/or respiratory symptoms that are concerning for COVID-19 should be tested for SARS-CoV-2 as soon as possible. HCW who have had unprotected exposure to a person with confirmed COVID-19 but remain asymptomatic should be tested immediately and 3–5 days following the date of exposure at a minimum. Specific routine staff testing is required or recommended by federal and/or state guidelines in skilled nursing or assisted living facilities. Please refer to the following guidance for detailed testing recommendations, which have been updated to discuss recommendations for vaccinated HCWs: . COVID-19 Testing Recommendations for Long-term Care Facilities (www.health.state.mn.us/diseases/coronavirus/hcp/ltctestrec.pdf) HCW with exposure to COVID-19 MDH and health care organizations cooperate to identify, manage, and monitor HCW who have experienced a high-risk (unprotected) exposure to a patient, resident, co-worker, or household/social contact with confirmed COVID-19. Most HCW who have had a high-risk exposure are identified through occupational tracking of personal protective equipment (PPE) breaches and/or contact tracing and assessment of PPE worn while in contact with a COVID-19 positive patient, resident, or co-worker.
    [Show full text]